TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3871797
Drug: Enteric-coated erythromycin
Normalized name: erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enteric-coated erythromycin pellets (250 mg base)
Study: 3871797
Drug: Erythromycin ethylsuccinate
Normalized name: Erythromycin Ethylsuccinate
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythromycin ethylsuccinate (400 mg base equivalent)
Study: 3622938
Drug: Cisapride (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride (20 mg p.o.)
Study: 25978046
Drug: Melissa officinalis
Normalized name: melissa officinalis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melissa officinalis extract containing 500 mg rosmarinic acid (fasted state)
Study: 25978046
Drug: Melissa officinalis
Normalized name: melissa officinalis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melissa officinalis extract containing 500 mg rosmarinic acid (fed state)
Study: 25978046
Drug: Melissa officinalis
Normalized name: melissa officinalis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melissa officinalis extract containing 500 mg rosmarinic acid
Study: 19114860
Drug: Therapeutic drug
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic drug monitoring (TDM) with protease inhibitor dose escalation
Study: 15663123
Drug: Carbohydrate solution
Normalized name: phosphorated carbohydrate solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate solution (25 g carbohydrates)
Study: 9150807
Drug: Vigabatrin (VGB)
DrugBank: Vigabatrin (DB01080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vigabatrin (VGB) add-on treatment
Study: 7919566
Drug: Tacrine (cholinesterase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrine (cholinesterase inhibitor)
Study: 3585450
Drug: Controlled-release morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release morphine sulfate (MSC)
Study: 31843338
Drug: Chemotherapy (182
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (182 patients)
Study: 31843338
Drug: Reduced high‐dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduced high‐dose volume radiotherapy (111 patients)
Study: 30989173
Drug: Augmentor software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmentor software package for image augmentation
Study: 27900942
Drug: GFR <
Normalized name: Glomerular Filtration Rate
Approvals — FDA: no, EMA: no, PMDA: no
Description: GFR < 45 mL/min/1.73 m2
Study: 27900942
Drug: GFR ≥
Normalized name: Glomerular Filtration Rate
Approvals — FDA: no, EMA: no, PMDA: no
Description: GFR ≥ 90 mL/min/1.73 m2
Study: 26322635
Drug: 30‐mL balloon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30‐mL balloon for a maximum of 12 hours
Study: 26322635
Drug: 30‐mL balloon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30‐mL balloon for a maximum of 24 hours
Study: 26322635
Drug: 80‐mL balloon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80‐mL balloon for a maximum of 12 hours
Study: 26322635
Drug: 80‐mL balloon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80‐mL balloon for a maximum of 24 hours
Study: 26322635
Drug: Higher balloon
Normalized name: CATHETER,BALLOON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher balloon volume (80‐mL) and longer ripening time (24 hours)
Study: 16879332
Drug: Conventional buccal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional buccal infiltration (CBi)
Study: 16879332
Drug: Periodontal ligament
Normalized name: human ligament preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periodontal ligament injection (PDLi)
Study: 11421896
Drug: Nedocromil sodium,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nedocromil sodium, two puffs twice daily, 0.002 g/puff
Study: 11421896
Drug: Placebo, two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, two puffs twice daily
Study: 9508754
Drug: Diacarb administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diacarb administered after the proposed protocols
Study: 8514653
Drug: Once-daily dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily dosing of netilmicin (6 mg/kg body weight)
Study: 8514653
Drug: Thrice-daily dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrice-daily dosing of netilmicin (6 mg/kg body weight)
Study: 8514653
Drug: Thrice-daily dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrice-daily dosing of netilmicin
Study: 3734289
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 2.2 or 4.4 mg of azelastine
Study: 3734289
Drug: Multiple dose
Normalized name: Rebetron, multiple dose 600 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple dose therapy with 4.4 mg of azelastine for 21 days
Study: 30531384
Drug: L‐dopa ON
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐dopa ON
Study: 30531384
Drug: L‐dopa OFF
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐dopa OFF
Study: 30531384
Drug: Practice dose
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Practice dose and acquisition rate
Study: 25917017
Drug: Electrical stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrical stimulation therapy on the suprahyoid muscles (SM group, n = 66)
Study: 25917017
Drug: Electrical stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrical stimulation therapy with electrodes on both suprahyoid and infrahyoid muscles (SI group, n = 66)
Study: 19751115
Drug: Amlodipine/valsartan (10/160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine/valsartan (10/160 mg o.d.)
Study: 19751115
Drug: Amlodipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (10 mg o.d.)
Study: 16954960
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (10 mg for 14 days)
Study: 9284731
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth Hormone (GH) 0.036 U/kg.day
Study: 29537647
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogen (CEE, 0.625 mg/day) + medroxyprogesterone acetate (MPA, 2.5 mg/day)
Study: 11360606
Drug: Levonorgestrel (LNG)
Normalized name: Levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levonorgestrel (LNG) 0.75 mg taken twice with 12 hours apart
Study: 11360606
Drug: Mifepristone (Mife-)
DrugBank: Mifepristone (DB00834)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mifepristone (Mife-) single dose of 10 mg and placebo 12 hours after
Study: 7484025
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 0.5 times the ED50 doses of mivacurium and pancuronium (cMP)
Study: 7484025
Drug: cMP administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: cMP administered to the same IV-line
Study: 7484025
Drug: cMP administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: cMP administered to two separate IV-lines in opposite hands
Study: 1322075
Drug: Metronidazole (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (500 mg twice daily for 10 days)
Study: 1322075
Drug: Placebo (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (three times daily for 10 days)
Study: 6095356
Drug: Imipramine (after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (after treatment)
Study: 31663443
Drug: ADC gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADC gel
Study: 24578470
Drug: Control (glucose-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (glucose-based dialysis solution)
Study: 17885238
Drug: Endovascular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular therapy (retreatment)
Study: 17885238
Drug: Endovascular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular therapy (retreatment) for small aneurysms (< or =10 mm) with small necks (< or =4 mm)
Study: 17885238
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with residual aneurysm after the first treatment
Study: 15070873
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist (0.1 mg triptorelin)
Study: 11576319
Drug: Anti-hypertensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-hypertensive treatment for 3 months with a calcium-antagonist in randomized combination with either an ACE inhibitor or a beta-blocker
Study: 9592630
Drug: Other antidepressants
Normalized name: Other antidepressants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other antidepressants or lithium
Study: 8169616
Drug: High-dose nicardipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose nicardipine (0.15 mg/kg/hr)
Study: 8169616
Drug: Low-dose nicardipine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose nicardipine (0.075 mg/kg/hr)
Study: 8169616
Drug: High-dose nicardipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose nicardipine
Study: 8169616
Drug: Low-dose nicardipine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose nicardipine
Study: 30115326
Drug: C. etunicatum
Approvals — FDA: no, EMA: no, PMDA: no
Description: C. etunicatum + G. albida
Study: 11039202
Drug: IFN a-2
Normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN a-2 monotherapy (10 million I.U. in 50 ml physiological saline)
Study: 11039202
Drug: IFN a-2
Normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN a-2 + Farmarubicin (FRC) combination (50 mg in 50 ml physiological saline)
Study: 11039202
Drug: IFN a-2
Normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN a-2 monotherapy and IFN a-2 + FRC combination (Group I + II)
Study: 11039202
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (Control Group III)
Study: 31523892
Drug: Neladenoson bialanate
Normalized name: Neladenoson bialanate
DrugBank: Neladenoson bialanate (DB13138)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neladenoson bialanate (5, 10, 20, 30, and 40 mg)
Study: 18044259
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g ascorbic acid
Study: 11875333
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol (0.025 mg/day) and norethisterone acetate (0.125 mg/day)
Study: 10435260
Drug: Standard program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard program (longer inpatient treatment)
Study: 10435260
Drug: Abbreviated Inpatient
Normalized name: Impatiens irvingii whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abbreviated Inpatient program (shorter inpatient treatment)
Study: 7787134
Drug: Furosemide controlled
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Furosemide controlled release formulation (FR) with breakfast
Study: 7787134
Drug: Furosemide controlled
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Furosemide controlled release formulation (LR) with breakfast
Study: 7787134
Drug: Furosemide controlled
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Furosemide controlled release formulation (FR) fasting
Study: 7787134
Drug: Furosemide controlled
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Furosemide controlled release formulation (LR) fasting
Study: 2186825
Drug: Banked donor
Normalized name: Donor Human Stool
DrugBank: Fecal microbiota (DB17743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Banked donor milk or preterm formula as sole diet or supplement to mother's expressed breast milk in trial A
Study: 203635
Drug: BRL 5907
Approvals — FDA: no, EMA: no, PMDA: no
Description: BRL 5907 (5 mg per day for three days)
Study: 28580708
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin (OXT) 24 IU
Study: 21300350
Drug: Fluvastatin (10mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin (10mg daily for 30 days)
Study: 16721398
Drug: Low-fat cheese
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fat cheese enriched with 2 g of plant stanols per day
Study: 15201248
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg oral dose of oestradiol
Study: 15201248
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg oestradiol orally/day for 12 weeks
Study: 11167171
Drug: isobaric mepivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: isobaric mepivacaine 20 mg/ml
Study: 11167171
Drug: isobaric lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: isobaric lidocaine 20 mg/ml
Study: 9315790
Drug: Triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone acetonide inhalation aerosol (TAA) 200 microg (1 puff bid)
Study: 9315790
Drug: Triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone acetonide inhalation aerosol (TAA) 400 microg (2 puffs bid)
Study: 9315790
Drug: Triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone acetonide inhalation aerosol (TAA) 800 microg (4 puffs bid)
Study: 9315790
Drug: Triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone acetonide inhalation aerosol (TAA) 1600 microg (8 puffs bid)
Study: 8361220
Drug: Induction therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction therapy with three drugs, CNS protection with cranial irradiation 18Gy or 24Gy, maintenance therapy for 120 weeks (GBTLI-80)
Study: 8361220
Drug: Induction therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction therapy with three drugs, CNS protection with cranial irradiation 18Gy or 24Gy, continuous maintenance for 2 years (GBTLI-82)
Study: 8361220
Drug: No cranial
Approvals — FDA: no, EMA: no, PMDA: no
Description: No cranial radiation, CNS protection with triple intrathecal therapy, consolidation therapy with high dose ARA-C for high risk patients (GBTLI-85)
Study: 2940953
Drug: Cromolyn sodium
Normalized name: Cromolyn Sodium
DrugBank: Cromoglicic acid (DB01003)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cromolyn sodium (200 mg by spinhaler) + Atropine sulfate (2.0 mg by nebulizer)
Study: 2940953
Drug: Cromolyn sodium
Normalized name: Cromolyn Sodium
DrugBank: Cromoglicic acid (DB01003)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cromolyn sodium (200 mg) + Ipratropium bromide (200 micrograms)
Study: 2940953
Drug: Cromolyn sodium
Normalized name: Cromolyn Sodium
DrugBank: Cromoglicic acid (DB01003)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cromolyn sodium (200 mg)
Study: 2940953
Drug: Atropine sulfate
Normalized name: Atropine Sulfate
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atropine sulfate (2.0 mg)
Study: 27436469
Drug: Enhanced therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced therapy (doxycycline and ceftriaxone)
Study: 27436469
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (benzathine penicillin G)
Study: 25193534
Drug: Low-dose UPA-CVR
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose UPA-CVR (1500 μg/day)
Study: 25193534
Drug: High-dose UPA-CVR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose UPA-CVR (2500 μg/day)
Study: 25193534
Drug: Levonorgestrel (LNG)
Normalized name: Levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levonorgestrel (LNG) 1.5 mg orally
Study: 22994618
Drug: Home-based physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based physical therapy once a month for 6 months, along with educational support, counselling and audiovisual materials
Study: 18396455
Drug: Zonisamide (ZNS)
Normalized name: Zonisamide
DrugBank: Zonisamide (DB00909)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Zonisamide (ZNS) 200 mg/day for 8 weeks
Study: 17338717
Drug: ICD therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICD therapy in patients with CKD
Study: 17338717
Drug: ICD therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICD therapy in patients without CKD
Study: 15284015
Drug: 10.5 mg
Normalized name: pectin 10.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10.5 mg total dose (three vials of SALon)
Study: 15284015
Drug: 17.5 mg
Normalized name: acitretin 17.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17.5 mg total dose (five vials of SALon)
Study: 11876441
Drug: Tramadol 50
Normalized name: traMADol 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 50 mg capsules
Study: 11876441
Drug: Tramal 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramal 50 mg capsules (control)
Study: 2893867
Drug: biosynthetic human
Normalized name: Proinsulin biosynthetic human
DrugBank: Proinsulin human (DB17875)
Approvals — FDA: no, EMA: no, PMDA: no
Description: biosynthetic human growth hormone (BSHGH) 0.1 mg/kg daily for the first 7 postoperative days
Study: 20921837
Drug: Intrathecal bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal bupivacaine 0.5% (15 mg), morphine 0.4 mg, and fentanyl 15 μg
Study: 20921837
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine 0.4 mg and fentanyl 15 μg
Study: 8928187
Drug: Synthetic human
Normalized name: Synthetic human secretin
DrugBank: Secretin human (DB09532)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Synthetic human insulin infused at 40 mU/m2/min for 2 hr
Study: 8928187
Drug: 10% xylitol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% xylitol infused at 100 ml/hr for 2 hr (control)
Study: 1824218
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g salt per day diet (Group I)
Study: 1824218
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g salt per day diet (Group II)
Study: 6787909
Drug: Glucose-insulin-potassium (G-I-K)
Normalized name: glucose / potassium chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose-insulin-potassium (G-I-K) infusion (300 gm of glucose, 50 units of insulin, and 80 mEq of KCl per liter at a rate of 1.5 ml/kg/hr for 48 hours)
Study: 24335748
Drug: ED treatment
Normalized name: NOSEBLEED TREATMENT KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: ED treatment after 12 weeks
Study: 24335748
Drug: Non-drug, run-in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-drug, run-in period (4 weeks)
Study: 22673926
Drug: Oseltamivir (Tamiflu®)
Normalized name: oseltamivir Oral Suspension [Tamiflu]
DrugBank: Oseltamivir (DB00198)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oseltamivir (Tamiflu®) 75 mg single dose
Study: 22145462
Drug: Low Insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low Insulin Response Diet (LIR)
Study: 10940701
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (radiotherapy with neoadjuvant cisplatin)
Study: 8258615
Drug: Flunisolide nasal
Normalized name: flunisolide nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunisolide nasal spray (100 micrograms)
Study: 3910429
Drug: Epidural analgesia
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural analgesia (G-II)
Study: 3910429
Drug: Standard anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard anaesthesia (G-I)
Study: 29913001
Drug: Rituximab (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (2 infusions of 375 mg/m2)
Study: 29913001
Drug: Tacrolimus (along
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrolimus (along with tapering alternate-day prednisolone for 12 months)
Study: 24913242
Drug: Intraoperative 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative 1 mg morphine bolus (Group B)
Study: 24913242
Drug: Intraoperative 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative 2 mg morphine bolus (Group C)
Study: 24913242
Drug: Continuous epidural
Normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous epidural morphine infusion of 0.2 mg/h with 0.1% levobupivacaine via PCEA (all groups)
Study: 24913242
Drug: No intraoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: No intraoperative morphine loading (Group A)
Study: 21300723
Drug: Skeletal anchorage
Normalized name: Spongia officinalis skeleton extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skeletal anchorage (Onplant or Orthosystem implant)
Study: 10866044
Drug: Low glucosamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low glucosamine infusion (1.6 micromol x min(‐1) x kg(‐1))
Study: 10866044
Drug: High glucosamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High glucosamine infusion (5 micromol x min(‐1) x kg(‐1))
Study: 9174428
Drug: Goserelin 3.6
Normalized name: goserelin 3.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goserelin 3.6 mg subcutaneous implant 4-6 weeks preoperatively (Group B)
Study: 9174428
Drug: Goserelin 3.6
Normalized name: goserelin 3.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goserelin 3.6 mg subcutaneous implant 4-6 weeks preoperatively and repeated on the day of endometrial resection (Group C)
Study: 9174428
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Group A, no preoperative preparation)
Study: 17314338
Drug: Valacyclovir (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valacyclovir (500 mg twice daily)
Study: 19493958
Drug: modafinil (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: modafinil (300 mg)
Study: 19493958
Drug: prazosin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: prazosin (3 mg)